DBV Technologies stock rebounds against the tide as SBF 120 slides into red
The Châtillon-based biotech company closed its trading session on Wednesday, September 2nd in marked resilience against a declining SBF 120, ranking among the rare gainers in the broad index. The rebound occurred after the stock touched an intraday low before recovering to close in positive territory.
A late-session rebound that does not challenge the downward pressure from moving averages
DBV Technologies closed at €2.37, up 2.42% from the previous day (€2.316), in a Paris market generally oriented downward (CAC 40: -0.26% at close). The session was nonetheless turbulent: the stock broke through its €2.31 support level during the session, falling to a low of €2.30, before rallying above this threshold to finish at €2.37. This rebound from the day's trough is insufficient to erase the structural pressure reflected by moving averages.
The price remains below the 20-day moving average at €2.44 (gap of -2.79%) and the 50-day moving average at €2.57 (gap of -7.70%), confirming a bearish dynamic in the short to medium term. The RSI at 39, while not in outright oversold territory, reflects a depletion of buying momentum accumulated in recent weeks. Over seven days, the stock fell a further 6.25% and declined 26.74% over three months, although the year-to-date performance remains strongly marked at +50.13%.
Short positions still present as the biotech awaits a key regulatory decision
Three funds combined hold 3.39% of DBV Technologies capital in net short positions, according to filings consulted (last updated August 28, 2026). This level, slightly lower than the 3.60% recorded thirty days ago (-0.21 percentage point), nonetheless remains elevated: it reflects the caution of institutional investors who maintain a bearish bet on the stock, without amplifying their recent exposure. This type of positioning merits monitoring over time, without attributing a unique significance to it, since the motivations (hedging a broader portfolio, anticipating dilution, fundamental conviction) remain unknown.
On the fundamental front, upon publishing Q1 2026 results (April 30, 2026), the company reported net losses rising to $47.6 million and a significant increase in its R&D expenses, while confirming the filing of a biologics license application scheduled for 2026. This regulatory milestone remains the principal fundamental benchmark for the months ahead. Analyst consensus on the value should be monitored as this timeline becomes clearer.
